

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6866

**Title:** Treatment of Early Gastric Cancer in the Western World

**Reviewer code:** 01003401

**Science editor:** Qi, Yuan

**Date sent for review:** 2013-10-30 19:29

**Date reviewed:** 2013-11-26 09:42

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Dear authors: The authors described the methods of treating the gastric cancer and the topic is also very useful for clinical application. However, the information about the treatment modalities for gastric cancer should be described completely. Chemotherapy and nanoimmunotherapy were used to treat the gastric cancer, but this important information is missing in the manuscript. The authors should add them to the manuscript. Some references about Chemotherapy and nanoimmunotherapy are listed below. 1. Biomaterials. 2012,33(21):5349-62 2. Mini Rev Med Chem. 2013,13(5):643-52 3. Nanomedicine, 2013, (Lond), 2013, 8 (5),679-682. 4. Mol Cancer Ther, 2006, 5:1909-1917. 5. Nanomedicine (Lond). 2013,8(7):1067-84 6. Nature Nanotechnology, 6, 675-682 (2011)

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 6866

**Title:** Treatment of Early Gastric Cancer in the Western World

**Reviewer code:** 00052261

**Science editor:** Qi, Yuan

**Date sent for review:** 2013-10-30 19:29

**Date reviewed:** 2013-12-08 20:18

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Different situations in treatments of early gastric cancer between Asian and Western world, are well compared and summarized in the present manuscript. Moreover, definition, epidemiology and various therapeutic options about early gastric cancer are well reviewed. If authors provide more description about following subjects, this manuscript will be more fruitful. 1. As authors described, the key issue is lymph node metastasis in the decision of EMR or ESD. Recently many are trying to predict lymph node metastasis or to make new criteria for EMR or ESD. If authors provide more review on this area, it will be helpful. 2. Authors mentioned higher frequency of LNM in pT1 gastric cancer patients of European countries than Asian countries. Could authors explain why this difference occurs? Are there biological differences between two worlds? Are there differences in genomic or epigenomic changes between two worlds?